Citations

Mayo Clinic

Showing 10 of 108537 citations.

Safety and efficacy of resmetirom in the treatment of patients with non-alcoholic steatohepatitis and liver fibrosis: a systematic review and meta-analysis
Raja, Adarsh , Sagar, Raja Subhash , Haq, Amna, Bhimani, Parshant Dileep, Deepak, Fnu , Shafique, Muhammad Ashir , Mustafa, Muhammad Saqlain , Sharma, Varsha , Sohaib Asghar, Muhammad, Saeed, Sadia, Khan, Owais, Raja, Sandesh , Ahmed, Muhammad , Asghar, Muhammad Sohaib

Annals of Medicine & Surgery | May 21, 2024 | Volume: 86 | Issue: 7 | Pages: 4130-4138

10.1097/ms9.0000000000002195 | PMID 38989228 Get It

Introduction: Non-alcoholic fatty liver disease (NAFLD), spanning from non-alcoholic steatohepatitis (NASH) to liver fibrosis, poses a global health challenge amid rising obesity and metabolic syndrome rates. Effective pharmacological treatments for NASH and liver fibrosis are limited. Objective: This study systematically reviews and meta-analyzes the safety and efficacy of resmetirom, a selective thyroid hormone receptor-β agonist, in NASH and liver fibrosis treatment. By analyzing data from clinical trials, we aim to offer evidence-based recommendations for resmetirom’s use in managing these conditions and identify avenues for future research. Methods: Electronic databases (PubMed, Scopus, Science Direct, Google Scholar, ClinicalTrials.gov, and Cochrane CENTRAL) were systematically searched, supplemented by manual screening of relevant sources. Only English-language randomized controlled trials were included. Data extraction, risk of bias assessment, pooled analyses, and meta-regression were performed. Results: Three randomized controlled trials involving 2231 participants were analyzed. Resmetirom demonstrated significant reductions in hepatic fat fraction [standardized mean difference (SMD) −4.61, 95% CI −6.77 to −2.44, P < 0.0001], NASH resolution without worsening fibrosis [risk ratio (RR) 2.51, 95% CI 1.74–3.64, P = 0.00001), and liver fibrosis improvement (RR 2.31, 95% CI 1.20–4.44, P = 0.01). Secondary outcomes showed significant improvements in lipid profiles, liver enzymes, and NASH biomarkers with resmetirom treatment. Meta-regression revealed associations between covariates and primary outcomes. Conclusion: Resmetirom exhibits promising efficacy in reducing hepatic fat, improving NASH resolution, and ameliorating liver fibrosis with a favorable safety profile. Further research is warranted to validate findings and optimize therapeutic strategies for NASH and liver fibrosis management.
Cancer Surveillance in Solid Organ Transplant Recipients With a Pretransplant History of Malignancy: Multidisciplinary Collaborative Expert Opinion
Watt, Kymberly D., Rolak, Stacey , Foley, David P. , Plichta, Jennifer K. , Pruthi, Sandhya , Farr, Deborah , Zwald, Fiona O. , Sanger, Cristina B. , Ricciardi, Rocco , Chang, George J. , Dizon, Don S. , Teoh, Deanna , Al‐Qaoud, Talal , Eggener, Scott E. , Kennedy, Cassie C. , D’Cunha, Jonathan, Mohindra, Nisha , Stewart, Shelby , Habermann, Thomas, Lunning, Matthew A. , Shah, Nirav N. , Mehta, Jayesh, Verna, Elizabeth C. , Hammel, Laura L., Al‐Adra, David , D'Cunha, Jonathan, Habermann, Thomas H, Kennedy, Cassie C , Plichta, Jennifer K , Carvajal, Richard D. , Dudek, Arkadiusz Z. , Langstraat, Carrie , Agarwal, Piyush Kumar , Schuster, Stephen J. , Gertz, Morie A. , Suvannasankha, Attaya , Farr, Maryjane , Blosser, Christopher D.

Transplantation | May 21, 2024 | Volume: 108 | Issue: 12 | Pages: 2336-2350

10.1097/tp.0000000000005056 | PMID 38771067 Get It

With improved medical treatments, the prognosis for many malignancies has improved, and more patients are presenting for transplant evaluation with a history of treated cancer. Solid organ transplant (SOT) recipients with a prior malignancy are at higher risk of posttransplant recurrence or de novo malignancy, and they may require a cancer surveillance program that is individualized to their specific needs. There is a dearth of literature on optimal surveillance strategies specific to SOT recipients. A working group of transplant physicians and cancer-specific specialists met to provide expert opinion recommendations on optimal cancer surveillance after transplantation for patients with a history of malignancy. Surveillance strategies provided are mainly based on general population recurrence risk data, immunosuppression effects, and limited transplant-specific data and should be considered expert opinion based on current knowledge. Prospective studies of cancer-specific surveillance models in SOT recipients should be supported to inform posttransplant management of this high-risk population.
Use of Federal Reimbursement for Living Donor Costs by Racial and Ethnic Minorities: Implications for Disparities in Access to Living Donor Transplantation
Mathur, Amit K. , Goodrich, Nathan P. , Mandell, Rebecca , Warren, Patricia H., Ojo, Akinlolu , Merion, Robert M. , Hong, Barry A. , Smith, Abigail R. , Gifford, Kimberly A.

Transplantation | May 21, 2024 | Volume: 108 | Issue: 12 | Pages: 2409-2419

10.1097/tp.0000000000005013 | PMID 38771064 Get It

Background. Minority race, ethnicity, and financial barriers are associated with lower rates of living donor (LD) kidney transplantation (LDKT). Financial reimbursement for LD costs may impact social determinants of health and, therefore, impact disparities in access to LDKT. Methods. Among US LDKTs, we studied associations between racial and ethnic minority status and utilization of the National Living Donor Assistance Center (NLDAC), a means-tested reimbursement program for nonmedical LD costs. We analyzed demographic, clinical, income, and survey data from NLDAC and the Scientific Registry of Transplant Recipients (January 1, 2011, to December 31, 2022) to identify predictors of NLDAC utilization. Results. Among 70 069 US LDKTs, 6093 NLDAC applicants were identified (9% of US LDKTs). Racial and ethnic minorities were over-represented in NLDAC-supported LDKTs compared with non-NLDAC US LDKTs (Black donors 12% versus 9%; Black recipients 15% versus 12%; Hispanic donors 21% versus 14%; Hispanic recipients 23% versus 15%; all P < 0.001). Among preemptive transplants, use of NLDAC by donors to Hispanic recipients (11%) was nearly twice as high as that of non-Hispanic recipients (6%) (P < 0.001). At time of NLDAC application, 72% stated NLDAC “will make it possible” to donate; higher proportions of minority applicants agreed (Black 80%, White 70%, P < 0.001; Hispanic 79%, non-Hispanic 70%, P < 0.001). Racial and ethnic minority-concordant transplants were significantly more likely to use NLDAC (donor/recipient: Black/Black risk-adjusted odds ratio [OR], 1.85, other/other OR 2.59, Hispanic/Hispanic OR 1.53; all P < 0.05). Conclusions. Reduction of LD financial barriers may increase access to LDKT, particularly in racial and ethnic minority communities.
VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic): clinical review in a rapidly emerging field
Phan, Luan , Patnaik, Mrinal M. , Pemmaraju, Naveen , Hammond, Danielle , Wilson, Nathaniel R. , Groarke, Emma M

Leukemia & Lymphoma | May 21, 2024 | Volume: 65 | Issue: 9 | Pages: 1245-1257

10.1080/10428194.2024.2349950 | PMID 38770970 Get It

Safety and efficacy of continuous terlipressin infusion in HRS-AKI in a transplant population
Reddy, K. Rajender , Izzy, Manhal , Frederick, R. Todd , Rubin, Raymond A. , Fricker, Zachary , Ikahihifo-Bender, Jade , Harte, Maggie , Garcia, Sandra, Campbell, Kathryn, Olofson, Amy , Razavi, Ryan F., James, Janelle M., Patel, Het , Kim-Lee, Grace, Witkiewicz, Sherry , Tobin, William, Jamil, Khurram , Weinberg, Ethan M , Gonzalez, Stevan A , Izzy, M , Simonetto, Douglas A , Frederick, R Todd , Rubin, Raymond A , Ikahihifo-Bender, Jade , Olofson, Amy , Kim-Lee, Grace , Witkiewicz, Sherry , Jamil, Khurram , Weinberg, Ethan M. , Simonetto, Douglas A.

Liver Transplantation | May 21, 2024 | Volume: 30 | Issue: 10 | Pages: 1026-1038

10.1097/lvt.0000000000000399 | PMID 38771635 Get It

Hepatorenal syndrome-acute kidney injury (HRS-AKI) is associated with significant morbidity and mortality. While liver transplantation is the definitive treatment, continuous terlipressin infusion for HRS-AKI may provide benefit and, as such, was assessed in a population composed of candidates for liver transplant (LT). Fifty hospitalized LT-eligible patients with HRS-AKI received a single bolus followed by continuous terlipressin infusion. Acute-on-chronic liver failure grade 3, serum creatinine (SCr)>5.0 mg/dL, or Model for End-Stage Liver Disease (MELD) ≥35 were exclusions. Fifty hospitalized patients who received midodrine and octreotide or norepinephrine for HRS-AKI served as a historical comparator cohort. Complete response (CR) was defined as a ≥30% decrease in SCr with end-of-treatment (EOT) SCr≤1.5, partial response as a ≥30% decrease in SCr with EOT SCr>1.5, and nonresponse as a <30% decrease in SCr. CR rate was significantly higher in the terlipressin cohort compared to the historical cohort (64% vs. 16%, p<0.001). Survival, while numerically higher in those who received terlipressin, was statistically similar (D30: 94% vs. 82%, p=0.12; D90: 78% vs. 68%, p=0.37). Renal replacement therapy (RRT) was more common among terlipressin NR than CR and PR (70% vs. 3% vs. 13%, p < 0.001). EOT MELD and SCr were significantly lower within terlipressin cohort (MELD: 19 vs. 25, SCr: 1.4 vs. 2.1 mg/dL, p<0.001). Sixteen of 40 terlipressin-treated patients received LT-alone (terlipressin CR in 10/16). One patient on terlipressin had a hypoxic respiratory failure that responded to diuretics; one possibly had drug-related rash. With continuous terlipressin infusion, a CR rate of 64% was observed with a favorable safety profile. Terlipressin use was associated with lower EOT MELD and SCr than the historical midodrine and octreotide/norepinephrine cohort; LT-alone was accomplished in a high proportion of complete terlipressin responders.
Pregnancy dedifferentiates memory CD8+ T cells into hypofunctional cells with exhaustion-enriched programs
Pollard, Jared M. , Hynes, Grace , Yin, Dengping , Gounari, Fotini , Alegre, Maria‐Luisa , Chong, Anita S. , Gounari, Fotini , Mandal, Malay

JCI Insight | May 21, 2024 | Volume: 9 | Issue: 13 | Pages: No page available

10.1172/jci.insight.176381 | PMID 38771643 Get It

Alloreactive memory, unlike naive, CD8 + T cells resist transplantation tolerance protocols and are a critical barrier to long-term graft acceptance in the clinic. We here show that semiallogeneic pregnancy successfully reprogrammed memory fetus/graft-specific CD8 + T cells (T FGS ) toward hypofunction. Female C57BL/6 mice harboring memory CD8 + T cells generated by the rejection of BALB/c skin grafts and then mated with BALB/c males achieved rates of pregnancy comparable with naive controls. Postpartum CD8 + T FGS from skin-sensitized dams upregulated expression of T cell exhaustion (T EX ) markers (Tox, Eomes, PD-1, TIGIT, and Lag3). Transcriptional analysis corroborated an enrichment of canonical T EX genes in postpartum memory T FGS and revealed a downregulation of a subset of memory-associated transcripts. Strikingly, pregnancy induced extensive epigenetic modifications of exhaustion- and memory-associated genes in memory T FGS , whereas minimal epigenetic modifications were observed in naive T FGS . Finally, postpartum memory T FGS durably expressed the exhaustion-enriched phenotype, and their susceptibility to transplantation tolerance was significantly restored compared with memory T FGS . These findings advance the concept of pregnancy as an epigenetic modulator inducing hypofunction in memory CD8 + T cells that has relevance not only for pregnancy and transplantation tolerance, but also for tumor immunity and chronic infections.
Tissue Ablation: Applications and Perspectives
Keum, Hyeongseop , Çevik, Enes , Demirlenk, Yusuf Mert , Atar, Dila , Saini, Gia , Sheth, Rahul A. , Öklü, Rahmi , Kim, Jinjoo , Demirlenk, Yusuf M, Oklu, Rahmi , Demirlenk, Yusuf M , Deipolyi, Amy R.

Advanced Materials | May 21, 2024 | Volume: 36 | Issue: 32 | Pages: No page available

10.1002/adma.202310856 | PMID 38771628 Get It

AbstractTissue ablation techniques have emerged as a critical component of modern medical practice and biomedical research, offering versatile solutions for treating various diseases and disorders. Percutaneous ablation is minimally invasive and offers numerous advantages over traditional surgery, such as shorter recovery times, reduced hospital stays, and decreased healthcare costs. Intra‐procedural imaging during ablation also allows precise visualization of the treated tissue while minimizing injury to the surrounding normal tissues, reducing the risk of complications. Here, the mechanisms of tissue ablation and innovative energy delivery systems are explored, highlighting recent advancements that have reshaped the landscape of clinical practice. Current clinical challenges related to tissue ablation are also discussed, underlining unmet clinical needs for more advanced material‐based approaches to improve the delivery of energy and pharmacology‐based therapeutics.
Airway-occluding Mucus Plugs and Cause-specific Mortality in Chronic Obstructive Pulmonary Disease
Mettler, Sofia K. , Sonavane, Sushilkumar K. , Grumley, Scott , Nath, Hrudaya , Yen, Andrew , Pistenmaa, Carrie L. , Estépar, Raúl San Jośe , Díaz, Alejandro A. , San Jose Estepar, Raul , Diaz, Alejandro A , Yen, Andrew C., Nardelli, Pietro , Cho, Michael H.

American Journal of Respiratory and Critical Care Medicine | May 21, 2024 | Volume: 209 | Issue: 12 | Pages: 1508-1510

10.1164/rccm.202401-0121le | PMID 38771048 Get It

Global Trends in Kidney Stone Awareness: A Time Series Analysis from 2004–2023
Aiumtrakul, Noppawit , Suppadungsuk, Supawadee , Krisanapan, Pajaree , Pinthusopon, Preyarat, Mao, Michael A. , Arayangkool, Chinnawat , Vo, Kristine B. , Wannaphut, Chalothorn , Miao, Jing , Cheungpasitporn, Wisit , Suppadungsuk, Supawadee , Krisanapan, Pajaree , Mao, Michael A , Arayangkool, Chinnawat , Vo, Kristine B , Miao, Jing , Cheungpasitporn, Wisit , Aiumtrakul, Noppawit , Wannaphut, Chalothorn , Thongprayoon, Charat

Clinics and Practice | May 21, 2024 | Volume: 14 | Issue: 3 | Pages: 915-927

10.3390/clinpract14030072 | PMID 38804404 Get It

Background: Despite the prevalence and incidence of kidney stones progressively increasing worldwide, public awareness of this condition remains unclear. Understanding trends of awareness can assist healthcare professionals and policymakers in planning and implementing targeted health interventions. This study investigated online search interest in “kidney stone” by analyzing Google Trends, focusing on stationarity of the trends and predicting future trends. Methods: We performed time series analysis on worldwide Google monthly search data from January 2004 to November 2023. The Augmented Dickey–Fuller (ADF) test was used to assess the stationarity of the data, with a p-value below 0.05 indicating stationarity. Time series forecasting was performed using the autoregressive integrated moving average to predict future trends. Results: The highest search interest for “kidney stone” (score 100) was in August 2022, while the lowest was in December 2007 (score 36). As of November 2023, search interest remained high, at 92. The ADF test was significant (p = 0.023), confirming data stationarity. The time series forecasting projected continued high public interest, likely reflecting ongoing concern and awareness. Notably, diverse regions such as Iran, the Philippines, Ecuador, the United States, and Nepal showed significant interest, suggesting widespread awareness of nephrolithiasis. Conclusion: This study highlighted that “kidney stone” is a consistently relevant health issue globally. The increase and stationarity of search trends, the forecasted sustained interest, and diverse regional interest emphasize the need for collaborative research and educational initiatives. This study’s analysis serves as a valuable tool for shaping future healthcare policies and research directions in addressing nephrolithiasis related health challenges.
Reply to Barajas-Ochoa: The Imperative to Integrate International Medical Graduates into the Infectious Diseases Physician-Scientist Pathway: Expanding Opportunities and Overcoming Barriers
Swartz, Talia H. , Apewokin, Senu , Carpenter, Stephen M. , Chakraborty, Rana , Dennis, Ann M. , Houpt, Eric R. , Surana, Neeraj K. , Zerr, Danielle M. , Pirofski, Liise-anne , Swartz, Talia H , Pirofski, Liise‐anne

The Journal of Infectious Diseases | May 21, 2024 | Volume: 230 | Issue: 3 | Pages: 781-782

10.1093/infdis/jiae272 | PMID 38775090 Get It